Photo from Asgard Therapeutics/X
Sep 10, 2024, 06:46
Asgard Therapeutics lead product AT-108 directly reprograms tumor cells within the TME
Asgard Therapeutics posted on X:
“Asgard Therapeutics’s new paper in Science showing how our lead product AT-108 directly reprograms tumor cells within the TME to become functional antigen-presenting dendritic cells, triggering strong anti-tumour responses.
More.”
Source: Asgard Therapeutics/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 17:57
Nov 14, 2024, 17:46
Nov 14, 2024, 17:46
Nov 14, 2024, 17:42
Nov 14, 2024, 17:14